AtriCure, Inc. filings document financial results, governance matters and capital arrangements for a Nasdaq-listed medical technology company focused on Afib, left atrial appendage management and post-operative pain management. Form 8-K reports furnish quarterly and annual results, amended financial guidance disclosures, product-revenue drivers and material definitive agreements, including an asset-based revolving credit facility involving AtriCure, LLC as a borrower.
Proxy filings cover board and shareholder voting matters, executive compensation, equity awards and related governance disclosures. The filings also identify AtriCure common stock as registered on the Nasdaq Global Market under the symbol ATRC.
AtriCure, Inc. reported strong Q1 2026 growth, with revenue of $141,249, up 14.3% from Q1 2025. U.S. sales reached $116,205, led by appendage management and pain management products, while international revenue rose 11.5%.
Gross margin improved to 77.4%, and the company swung from a $6,747 net loss to modest net income of $108. Operating cash outflow improved to $3,996, ending the quarter with $146,165 in cash and $61,000 of debt outstanding.
AtriCure, Inc. filed an amended report to correct and expand its 2026 financial guidance while releasing strong first quarter 2026 results. The company now projects full year 2026 revenue of $600 million to $610 million, adjusted EBITDA of $80 million to $82 million, adjusted earnings per share of $0.09 to $0.15, and net earnings per share of $0.00 to $0.04, with continued positive cash flow.
For the first quarter 2026, AtriCure generated revenue of $141.2 million, up 14.3% year over year, driven by 14.9% growth in U.S. sales and 11.5% international growth. Gross margin rose to 77.4%, income from operations improved to $0.5 million from a $6.0 million loss, and net income was $0.1 million compared to a $6.7 million loss a year earlier. Adjusted EBITDA nearly doubled to $17.1 million, reflecting higher sales and operating leverage.
AtriCure, Inc. reported solid first quarter 2026 results with continued growth and a return to profitability. Revenue reached $141.2 million, up 14.3% year over year, led by 14.9% growth in the U.S. driven by cryoSPHERE MAX, AtriClip FLEX-Mini and PRO-Mini, and the EnCompass clamp.
Gross margin improved to 77.4%, lifting income from operations to $0.5 million versus a $6.0 million loss a year ago. Net income was $0.1 million, or $0.00 per share, compared with a $0.14 loss per share. Adjusted EBITDA nearly doubled to $17.1 million, and management issued 2026 guidance for $600–$610 million revenue, $80–$82 million adjusted EBITDA, and adjusted EPS of $0.00–$0.04.
AtriCure Inc reports an institutional holding: Vanguard Capital Management beneficially owns 2,532,965 shares of common stock, representing 5.08% of the class.
The Schedule 13G lists voting and dispositive powers: sole power to vote 377,201 shares and sole dispositive power over 2,532,965 shares. The filing names affiliated Vanguard entities and is signed by a Vanguard officer.
AtriCure Inc reported a Schedule 13G filing showing Vanguard Portfolio Management beneficially owns 2,744,685 shares of Common Stock. The filing states this equals 5.51% of the class as of 03/31/2026 and that Vanguard Portfolio Management has sole dispositive power over 2,744,685 shares and sole voting power for 42,053 shares.
The filing attributes holdings to Vanguard Portfolio Management LLC and affiliated business divisions and is signed on behalf of Vanguard by Ashley Grim on 04/28/2026.
AtriCure, Inc. is asking stockholders to approve several items at its virtual 2026 annual meeting, including amendments to expand its equity compensation plans. The company seeks to add 1,500,000 shares to the 2023 Stock Incentive Plan and 750,000 shares to the 2018 Employee Stock Purchase Plan.
Stockholders are also being asked to elect nine directors for one-year terms, ratify Deloitte & Touche LLP as independent auditor for 2026, and approve an advisory "say-on-pay" vote on named executive officer compensation. The meeting will be held online on May 18, 2026; holders of AtriCure common stock as of March 26, 2026, when 50,634,808 shares were outstanding, are entitled to vote.
AtriCure Inc Schedule 13G/A Amendment No. 6: The Vanguard Group reports beneficial ownership of 0 shares of Common Stock, representing 0%. The filing notes an internal realignment on January 12, 2026 that disaggregated reporting by Vanguard subsidiaries. The amendment is signed by Ashley Grim on 03/26/2026.
AtriCure, Inc. Chief Scientific Officer Doraiswamy Vinayak reported an open-market sale of 5,000 shares of common stock. The shares were sold at a weighted average price of $29.83 per share, in multiple trades executed between $29.79 and $29.92. Following this transaction, he directly holds 96,875 shares of AtriCure common stock.
ATRC submitted a Form 144 notice reporting proposed sales of common stock awards. The filing lists Performance Shares: 1,561 with an award date of 03/01/2024 and three Restricted Stock items of 813, 1,578, and 1,048 shares with award dates of 03/01/2023 and 03/01/2024.
The securities are identified as being sold by the Issuer and are reported for sale under Rule 144; timing and cash‑flow treatment are not stated in the excerpt.
AtriCure, Inc. director Robert S. White exercised non-qualified stock options for 10,000 shares at $14.99 per share. These options were originally granted on May 25, 2016 and vested over four years. Following the exercise, he directly holds 122,174 shares of AtriCure common stock.